The U.S. Army's DEVCOM Chemical Biological Center signed a research agreement with the University of Hawaii in March 2025 to develop deployable bioprinting stations capable of printing skin grafts in forward-operating environments — a technology that joins battlefield trauma care with regenerative biomanufacturing.
In 2023, the Army reported that hemorrhage remained the leading cause of potentially survivable death on the battlefield for the third consecutive decade. The standard response hasn't changed: tourniquet, bandage, evacuate. But evacuation windows are widening, not narrowing — anti-access and area denial (A2AD) environments mean medevac can take hours, not minutes. The gap between what a medic can carry and what a wound needs is the space this technology is designed to fill.
The technology sits at the intersection of two trends: the maturation of extrusion-based bioprinting to the point of portability, and the military's recognition that future conflicts will require distributed medical manufacturing at the point of injury.
This is not a thought experiment. The CRADA between DEVCOM CBC and the University of Hawaii includes two joint work statements with specific milestones for deployable printers capable of operating in austere conditions across the Indo-Pacific theater.
The gap is quantified. A 2024 RAND study on casualty care in high-intensity scenarios estimated that up to 40% of hemorrhage-related field deaths could be prevented if point-of-injury care matched Role 2 capabilities. The difference between those two echelons is roughly the contents of a medic's backpack — and the weight of a bioprinter.
What deployable bioprinting actually means
Bioprinting, in its conventional lab form, is not new. Wake Forest's Institute for Regenerative Medicine published the first proof-of-concept for in situ skin bioprinting in 2019 — a mobile system that scanned a wound's dimensions with a 3D laser scanner and deposited layered dermal fibroblasts and epidermal keratinocytes in a fibrinogen-collagen hydrogel directly into the injury site. Bioprinted wounds in a porcine model showed accelerated closure, reduced contraction, and earlier formation of defined epidermal and dermal layers compared to cell spraying, the next-best alternative.
What has changed since 2019 is the size and weight envelope. The original Wake Forest prototype was a wheeled cart 79 cm wide and 77 cm deep — mobile within an operating room, but not something a medic carries. The partnership between the Center and the University of Hawaii targets a different form factor entirely: a deployable printer that fits inside a ruggedized case, operates on battery power, and can be operated by a medic with minimal training.
The core technical challenge is not the printing mechanism — extrusion nozzles have been miniaturized effectively. It is the bioink. Cell-based inks require cold chain storage, have limited shelf life outside an incubator, and need to remain viable through the printing process without shear-induced damage. DEVCOM CBC's Priscilla Lee, the lead bioengineering researcher on the project, has been developing biomaterials formulations specifically optimized for long-duration storage at ambient temperatures — a necessary precondition for any forward-deployable medical technology.
The technology stack
Three parallel technical approaches are converging on the same problem.
Extrusion-based in situ printing. The most mature approach. A print head mounted on a lightweight gantry or robotic arm scans the wound bed, then deposits cell-laden hydrogel layer by layer. The system uses this method, adapted from the Wake Forest prototype but with a redesigned form factor. The key innovation is the scanning-and-printing feedback loop: the printer maps wound geometry in real time, adjusts deposition paths for irregular wound shapes, and can layer different cell types — fibroblasts for the dermal layer, keratinocytes for the epidermis — in a single pass.
Laser-based bioprinting. Dr. Hao Liu at ETH Zurich has developed a laser bioprinter that uses filamented light (FLight) to solidify gelatin into hydrogel microfilaments. The technique achieves cell alignment precision at the 2–20 micrometer scale, which matters for printing structured tissues like muscle, tendon, or nerve — not just skin. Military relevance: nerve damage is the second most common long-term disability from combat injuries, and no current field treatment exists for it. The FLight technique was patented in 2024 and Liu's team is exploring field-hospital deployment scenarios with European defense research partners.
Handheld bioprinting. Quixotix Bioprinting, a spinout from NIT Rourkela, is developing a handheld device called AXL 1.0 that builds scaffolds on-demand without requiring a separate gantry or robotic positioning system. The form factor is roughly that of a caulking gun. The trade-off is deposition precision — handheld systems cannot match the spatial accuracy of gantry-mounted printers — but the operational advantage is that they can be deployed by a single medic without setup time. Quixotix is currently at TRL 4, with animal model testing underway.
The application pathway
The CRADA is structured in two phases. Phase 1 focuses on organ-on-a-chip and bioprinted skin models for chemical and biological threat testing — essentially, using bioprinted human tissue as a testbed for countermeasures against burn agents, nerve gases, and antibiotic-resistant wound infections. Phase 2, which is the longer-term objective, is the forward-deployable bioprinter itself, capable of producing not just skin grafts but also custom medical prototypes at what the Army calls "austere locations" — forward operating bases, shipboard medical bays, or mobile field hospitals.
The geographic framing is specific. The University of Hawaii's location within USINDOPACOM's area of operations is not incidental — the agreement explicitly cites "regional supply chain resilience" and "interoperability among regional allies" as objectives. Distributed manufacturing of medical supplies in the Indo-Pacific theater, where evacuation distances are measured in thousands of kilometers rather than dozens, has operational logic that a CONUS-based medical logistics chain cannot replicate.
Tides Medical, a commercial wound care company, has already brought a related product to market: the APLICOR 3D platform, which uses a patient's own adipose tissue to create customized grafts for acute and chronic wounds. The system includes an AI-powered wound detection tablet that generates a 3D file, a single-use bioprinter cartridge, and a scaffold kit. It received FDA clearance for chronic wound applications in 2024 and is now in clinical use across 12 U.S. hospital systems. While APLICOR 3D is designed for hospital settings rather than forward deployment, its integrated imaging-printing workflow validates the clinical pathway that the military version would follow. The company has not disclosed military contract discussions, but the technology transfer pathway from wound care to battlefield medicine is short.
Who is funding this
The funding structure for deployable bioprinting is unusual because it does not follow the standard VC-backed medtech pattern. The largest single source is the Center itself — a government R&D budget allocation under the Army Futures Command. DARPA's BEST program (BioElectronics to Sense and Treat), while focused on smart bandages rather than bioprinting, has a complementary budget of approximately $40 million across its performer teams for wound infection sensing and closed-loop treatment, which covers the diagnostic half of the same clinical problem.
Private capital is starting to flow. Auxilium Health, a Cleveland-based wound care startup developing bioaerogel dressings, closed a $3.4 million seed round in July 2026. The Wound Company raised $4.25 million in seed funding from Susa Ventures and Sozo Ventures in 2023 for its telehealth wound care platform. Neither is a bioprinting company specifically, but they form an enabling ecosystem: bioprinted skin grafts will need wound assessment platforms, payment models, and clinical workflows before they reach the battlefield, and these startups are building that infrastructure.
What is missing is dedicated venture capital for defence-specific bioprinting. The technology falls between two funding categories — regenerative medicine and defence health — with neither claiming it. No dedicated defence-biotech VC fund has emerged in the U.S., unlike the defence-tech and defence-robotics categories where Anduril, Shield AI, and others have created a recognizable asset class. The E2D fund (€500 million, launched by AVP and Earlybird in 2026 for dual-use defence tech) covers biotech in principle, but its first close did not include any bioprinting allocations.
What limits it
Three constraints separate the current state from field deployment.
Vascularization. A bioprinted skin graft thicker than approximately 200 micrometers cannot survive without a vascular network — cells at the center of the construct die from hypoxia before host blood vessels grow in. Current approaches use endothelial cell co-printing to seed microvascular networks, but none has demonstrated functional perfusion at the scale required for a full-thickness combat wound. The Wake Forest group has printed vascularized skin constructs in animal models with promising graft take rates, but the vessel maturation timeline is 10–14 days — too slow for the battlefield window.
Cell sourcing. Autologous cells (from the patient) require a biopsy and culture expansion, which takes 2–4 weeks under ideal conditions. Allogeneic cells (donor-derived) eliminate the wait but introduce immune rejection risk. The practical solution for battlefield use is likely an off-the-shelf allogeneic cartridge with short-course immunosuppression — a regulatory pathway that has precedent in allogeneic skin grafts but no precedent for bioprinted constructs.
Regulatory classification. A deployable bioprinter that prints living cells into a wound is classified as a combination product by the FDA — part device, part biologic, part drug (the hydrogel carrier). Combination products go through the Office of Combination Products, which has historically been the slowest FDA review pathway. The Army's device is being developed under the CRADA framework, which allows for certain regulatory flexibilities for military-specific products, but the pathway to human use in combat is still undefined. The APLICOR 3D system received 510(k) clearance as a device because it uses the patient's own tissue harvested during the same procedure — a different regulatory classification entirely. The military's system, using pre-manufactured cell cartridges, will almost certainly require a Biologics License Application.
Counter-approaches
Bioprinting is not the only candidate for battlefield wound repair. DARPA's BEST program, launched in February 2025, is developing an entirely different approach: a closed-loop bioelectronic smart bandage that senses wound infection markers and delivers targeted non-antibiotic treatments without printing any cells at all. The BEST device aims for TRL 5 by 2028 and targets the same clinical endpoint — preventing wound infection and promoting healing — via electronics and pharmacology rather than tissue engineering. The comparative advantage of BEST is that it does not require cell storage or viability management; its disadvantage is that it cannot replace lost tissue, only prevent infection in existing tissue.
Cell spraying, the technique that bioprinting aims to supersede, remains the most widely practiced form of cell-based wound treatment. The technology is simpler — a handheld spray gun deposits a cell suspension onto the wound bed — and has decades of clinical data behind it. The limitation is spatial precision: cell spraying cannot create layered skin structures with distinct dermal and epidermal layers, which is why bioprinted wounds in the porcine study showed measurably better outcomes on every histological parameter. But for a medic in the field, a cell spray gun that works today may be preferable to a bioprinter that requires training.
DEVCOM-UH Phase 2 milestones: the partnership's second joint work statement, focused on deployable printers, has not published specific delivery dates. A public milestone announcement would signal transition from R&D to engineering prototyping.
APLICOR 3D military adaptation: if Tides Medical announces a contract with USAMRMC or DARPA, it validates the commercial-to-military pathway for bioprinted wound care.
Regulatory precedent: the first FDA clearance of a combination product bioprinter — whether military or civilian — would set the framework for all subsequent devices.
VC entry: the first dedicated defence-biotech fund allocation to a bioprinting company would signal that the funding gap identified above is closing.
A defence investor should note the long-term economics of this shift. The U.S. military spends approximately $580 million annually on wound care products and dressings, according to a 2024 Defense Health Agency procurement analysis. A single severe burn casualty can incur $200,000–$500,000 in initial treatment costs, much of it driven by graft procurement and repeated debridement procedures. Bioprinted autologous skin, produced on-site from a small tissue biopsy, would eliminate the graft harvest site (itself a wound requiring care) and reduce the number of surgical procedures per casualty. Even at prototype-stage cost estimates, the per-patient savings would be substantial — and for a military planning high-intensity engagements with mass casualty projections, the aggregate numbers become a strategic argument, not just a clinical one.
The technology is not yet ready for a medic to carry into combat. The gap between the Wake Forest proof-of-concept (2019) and a ruggedized field prototype is still several years wide. But the direction of travel is clear: the Army has identified distributed biomanufacturing as a capability gap, has committed organizational resources through the Center and the CRADA mechanism, and is funding the biomaterials science needed to close the cold-chain and shelf-life barriers. The remaining question is not whether deployable bioprinting technology will eventually reach the battlefield — it is which technical pathway will get there first, and whether the regulatory infrastructure will be ready when it finally arrives.
